keyword
MENU ▼
Read by QxMD icon Read
search

Palivizumab

keyword
https://www.readbyqxmd.com/read/28188494/palivizumab-exposure-and-the-risk-of-atopic-dermatitis-asthma-and-allergic-rhinoconjunctivitis-a-cross-national-population-based-cohort-study
#1
Ann Haerskjold, Lonny Stokholm, Marie Linder, Simon Francis Thomsen, Gunnar Bergman, Ingegärd Anveden Berglind, Helle Kieler, Henrik Ravn, Lone Graff Stensballe
BACKGROUND: Palivizumab is a humanized monoclonal antibody designed to provide passive immunity against respiratory syncytial virus. It is prescribed to children at high risk for severe infection with respiratory syncytial virus. However, little is known about the risk of the immune-mediated diseases atopic dermatitis, asthma, and allergic rhinoconjunctivitis after palivizumab exposure. AIM: Our objective was to investigate whether exposure to palivizumab was associated with atopic dermatitis, asthma, or allergic rhinoconjunctivitis in childhood...
February 10, 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28187117/in-reply-statistical-power-to-detect-an-association-between-guideline-based-palivizumab-administration-and-hospitalizations-for-respiratory-syncytial-virus-infections
#2
Carlina J Grindeland, David D Leedahl
No abstract text is available yet for this article.
March 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28187116/statistical-power-to-detect-an-association-between-guideline-based-palivizumab-administration-and-hospitalizations-for-respiratory-syncytial-virus-infections
#3
Christopher S Ambrose
No abstract text is available yet for this article.
March 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28163166/respiratory-syncytial-virus-hospitalizations-in-infants-of-28-weeks-gestational-age-and-less-in-the-palivizumab-era
#4
Bernhard Resch, Beatrice Egger, Stefan Kurath-Koller, Berndt Urlesberger
OBJECTIVE: To obtain data on respiratory syncytial virus (RSV) associated hospitalization rates in preterm infants of 28 weeks gestational age and less in the era of palivizumab prophylaxis. METHODS: Retrospective single-center cohort study including all preterm infants up to 28 weeks+6days gestational age and born between 2004 and 2012 at a tertiary care university hospital. Data on RSV related hospitalizations over the first two years of life covering at least two RSV seasons (November-April) were analyzed...
February 2, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28152315/palivizumab-prophylaxis-in-preterm-infants-and-subsequent-recurrent-wheezing-6-year-follow-up-study
#5
Hiroyuki Mochizuki, Satoshi Kusuda, Kenji Okada, Shigemi Yoshihara, Hiroyuki Furuya, Eric A F Simões
RATIONALE: RSV (respiratory syncytial virus) induces not only infantile recurrent wheezing but also potentially atopic asthma. OBJECTIVES: To test the effect of RSV infection, on development of subsequent atopic asthma, we evaluated whether palivizumab, an anti-RSV monoclonal antibody, by preventing severe RSV disease in the first year of life, could impact subsequent recurrent wheezing and atopic asthma, at 6 years of age. METHODS: During the 2007-2008 RSV season, the decision to administer palivizumab was made based on standard medical practice, and an observational prospective multicenter (n=52) case-control study in preterm infants with a gestational age between 33 and 35 weeks followed from 0 to 3 years (preceeding CREW study)...
February 2, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28134915/structural-basis-for-antibody-cross-neutralization-of-respiratory-syncytial-virus-and-human-metapneumovirus
#6
Xiaolin Wen, Jarrod J Mousa, John T Bates, Robert A Lamb, James E Crowe, Theodore S Jardetzky
Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are two closely related viruses that cause bronchiolitis and pneumonia in infants and the elderly(1), with a significant health burden(2-6). There are no licensed vaccines or small-molecule antiviral treatments specific to these two viruses at present. A humanized murine monoclonal antibody (palivizumab) is approved to treat high-risk infants for RSV infection(7,8), but other treatments, as well as vaccines, for both viruses are still in development...
January 30, 2017: Nature Microbiology
https://www.readbyqxmd.com/read/28111638/rapid-profiling-of-rsv-antibody-repertoires-from-the-memory-b-cells-of-naturally-infected-adult-donors
#7
Morgan S A Gilman, Carlos A Castellanos, Man Chen, Joan O Ngwuta, Eileen Goodwin, Syed M Moin, Vicente Mas, José A Melero, Peter F Wright, Barney S Graham, Jason S McLellan, Laura M Walker
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in young children and the elderly. There are currently no licensed RSV vaccines, and passive prophylaxis with the monoclonal antibody palivizumab is restricted to high-risk infants in part due to its modest efficacy. Although it is widely agreed that an effective RSV vaccine will require the induction of a potent neutralizing antibody response against the RSV fusion (F) glycoprotein, little is known about the specificities and functional activities of RSV F-specific antibodies induced by natural infection...
December 16, 2016: Science Immunology
https://www.readbyqxmd.com/read/28105526/first-versus-second-year-respiratory-syncytial-virus-prophylaxis-in-chronic-lung-disease-2005-2015
#8
Daniel Y Wang, Abby Li, Bosco Paes, Ian Mitchell, Krista L Lanctôt
: Children aged <2 years with chronic lung disease (CLD) have a 10-fold higher risk for respiratory syncytial virus-positive hospitalization (RSVH) compared to healthy term infants. Based on the updated position statements, we compared respiratory-related illness hospitalization (RIH) and RSVH risks in CLD children who received palivizumab during the first year (FY) versus second year (SY) of life in the Canadian Registry of Palivizumab (CARESS). Demographic data were collected at enrolment and RIH events recorded monthly from 2005 to 2015...
January 20, 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/28089687/stabilizing-effects-for-antibody-formulations-and-safety-profiles-of-cyclodextrin-polypseudorotaxane-hydrogels
#9
Taishi Higashi, Naoko Ohshita, Tatsunori Hirotsu, Yoshihito Yamashita, Keiichi Motoyama, Sawako Koyama, Ruriko Iibuchi, Takayuki Uchida, Shiuhei Mieda, Kenji Handa, Tomoaki Kimoto, Hidetoshi Arima
Antibodies often have poor physicochemical stability during storage and/or transport, which is a serious drawback for the development of antibody-based drugs. In this study, we prepared polypseudorotaxane (PPRX) hydrogels consisting of cyclodextrins (CyDs) and polyethylene glycol (PEG), and evaluated them as stabilizers for commercially available antibody-based drugs. α-CyD and γ-CyD formed PPRX hydrogels with PEG (MW 20,000 Da) in the presence of antibody-based drugs such as omalizumab, palivizumab, panitumumab, and ranibizumab...
January 12, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28078558/respiratory-syncytial-virus-associated-hospitalizations-in-preterm-infants-of-29-to-32%C3%A2-weeks-gestational-age-using-a-risk-score-tool-for-palivizumab-prophylaxis
#10
B Resch, V S Bramreiter, S Kurath-Koller, T Freidl, B Urlesberger
To evaluate the efficacy of palivizumab in infants of 29 to 32 weeks of gestational age (GA) based on a risk score tool developed for Austria. Retrospective single-center cohort study including all preterm infants of 29 (+0) to 32 (+6) weeks of GA born between 2004 and 2012 at a tertiary care university hospital. Data on RSV-related hospitalizations over the first 2 years of life were analyzed and compared between those having received palivizumab and those without. The study population was comprised of 789 of 816 screened infants, of whom 262 (33%) had received palivizumab and 527 (67%) had not...
January 11, 2017: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/28005688/respiratory-syncytial-virus-infection-associated-hospitalization-rates-in-infants-and-children-with-cystic-fibrosis
#11
Jakob Metz, Ernst Eber, Bernhard Resch
BACKGROUND: Infections with respiratory syncytial virus (RSV) are the leading cause for hospital admissions in infants and young children. The incidence of RSV-related hospitalizations in patients with cystic fibrosis (CF) is unclear. To date no effective treatment for RSV infections is available. Thus, prophylaxis with the monoclonal antibody palivizumab is an important option. METHODS: In a retrospective, single-center study at the Department of Paediatrics and Adolescent Medicine of the Medical University Graz, Austria, we analyzed all CF patients born between 1995 and 2012, who were admitted for respiratory problems between 1995 and 2014...
December 21, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27989627/development-of-bioluminescence-imaging-of-respiratory-syncytial-virus-rsv-in-virus-infected-live-mice-and-its-use-for-evaluation-of-therapeutics-and-vaccines
#12
Sandra Fuentes, Diego Arenas, Martin M Moore, Hana Golding, Surender Khurana
Respiratory Syncytial virus (RSV) is one of the leading causes of pneumonia among infants with no human vaccine or efficient curative treatments. Efforts are underway to develop new RSV vaccines and therapeutics. There is a dire need for animal models for preclinical evaluation and selection of products against RSV. Herein, we developed a whole body bioluminescence imaging to follow replication of RSV A2 virus strain expressing firefly luciferase (RSVA2-line19-FFL) in live BALB/c mice that can be used as an extremely sensitive readout for studying effects of antiviral and vaccines in living mice...
December 15, 2016: Vaccine
https://www.readbyqxmd.com/read/27956428/safety-tolerability-and-pharmacokinetics-of-the-respiratory-syncytial-virus-prefusion-f-targeting-monoclonal-antibody-with-an-extended-half-life-medi8897-in-healthy-adults
#13
M Pamela Griffin, Anis A Khan, Mark T Esser, Kathryn Jensen, Therese Takas, Martin K Kankam, Tonya Villafana, Filip Dubovsky
Prevention of respiratory syncytial virus (RSV) illness in infants is a major public health priority, but there is no approved vaccine. Palivizumab is a monoclonal antibody that provides RSV prophylaxis but requires 5 monthly injections and is approved only for infants who experience the greatest morbidity and mortality from RSV. Thus, there remains a significant unmet medical need for prevention of RSV disease in healthy infants. MEDI8897 is a recombinant human RSV monoclonal antibody with a modified Fc region that extends its half-life and is being developed as RSV prophylaxis for all infants...
December 12, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27941187/factors-related-to-compliance-with-palivizumab-prophylaxis-for-respiratory-syncytial-virus-rsv-infection-data-from-poland
#14
Róża Borecka, Ryszard Lauterbach, Ewa Helwich
AIM: To evaluate compliance and health outcomes in children receiving palivizumab prophylaxis and to identify factors that could impact parental compliance with the recommended regimen of palivizumab immunoprophylaxis. MATERIAL AND METHODS: A retrospective, multicentre, non-interventional study of children enrolled in the Polish National Programme for Respiratory Syncytial Virus (RSV) Immunoprophylaxis who received ≥1 dose of palivizumab during two consecutive RSV seasons (I: 2008-2009, II: 2009-2010)...
2016: Developmental Period Medicine
https://www.readbyqxmd.com/read/27926583/evaluation-of-the-financial-and-health-burden-of-infants-at-risk-for-respiratory-syncytial-virus
#15
Stephanie McCallum Blake, David Tanaka, Lisa M Bendz, Suzanne Staebler, Debra Brandon
BACKGROUND: Respiratory syncytial virus (RSV) is the leading viral cause of death in infants younger than 1 year. In July 2014, the American Academy of Pediatrics (AAP) Committee on Infectious Diseases concluded that the "limited clinical benefit" for infants born at more than 29 weeks' gestation, together with the associated high cost of the immunoprophylaxis, no longer supported the routine use of palivizumab (Synagis). PURPOSE: To evaluate the impact of the newly adopted AAP palivizumab prophylaxis administration on health and subsequent hospital costs of infants born between 29 and less than 32 weeks' gestation...
December 6, 2016: Advances in Neonatal Care: Official Journal of the National Association of Neonatal Nurses
https://www.readbyqxmd.com/read/27919877/pharmacist-driven-respiratory-syncytial-virus-prophylaxis-stewardship-service-in-a-neonatal-intensive-care-unit
#16
Sara E Rostas, Christopher McPherson
PURPOSE: The development and implementation of a pharmacist-driven respiratory syncytial virus (RSV) prophylaxis stewardship program in a neonatal intensive care unit (NICU) are described. SUMMARY: An RSV prophylaxis stewardship service was created in the NICU at Brigham and Women's Hospital to align with the newly updated 2014 American Academy of Pediatrics (AAP) recommendations for palivizumab. The service comprised two NICU clinical pharmacists with oversight from the NICU medical director and the chair of the NICU infection control committee...
December 15, 2016: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27855996/impact-of-the-updated-guidance-for-palivizumab-prophylaxis-against-respiratory-syncytial-virus-infection-a-single-center-experience
#17
Bavani Rajah, Pablo J Sánchez, Cristina Garcia-Maurino, Amy Leber, Octavio Ramilo, Asuncion Mejias
OBJECTIVES: To determine the differences in number of respiratory syncytial virus (RSV) hospitalizations and outcomes in infants 29(0/7)-34(6/7) weeks' gestational age (wGA) the season before (season 1 [S1]; 2013-2014) and after (season 2 [S2]; 2014-2015) implementation of the 2014 American Academy of Pediatrics revised guidance for palivizumab prophylaxis. STUDY DESIGN: Children <12 months of age hospitalized with RSV infection were identified by the International Classification of Diseases, Ninth Revision codes and virology reports...
November 15, 2016: Journal of Pediatrics
https://www.readbyqxmd.com/read/27791117/structural-basis-for-nonneutralizing-antibody-competition-at-antigenic-site-ii-of-the-respiratory-syncytial-virus-fusion-protein
#18
Jarrod J Mousa, Marion F Sauer, Alexander M Sevy, Jessica A Finn, John T Bates, Gabriela Alvarado, Hannah G King, Leah B Loerinc, Rachel H Fong, Benjamin J Doranz, Bruno E Correia, Oleksandr Kalyuzhniy, Xiaolin Wen, Theodore S Jardetzky, William R Schief, Melanie D Ohi, Jens Meiler, James E Crowe
Palivizumab was the first antiviral monoclonal antibody (mAb) approved for therapeutic use in humans, and remains a prophylactic treatment for infants at risk for severe disease because of respiratory syncytial virus (RSV). Palivizumab is an engineered humanized version of a murine mAb targeting antigenic site II of the RSV fusion (F) protein, a key target in vaccine development. There are limited reported naturally occurring human mAbs to site II; therefore, the structural basis for human antibody recognition of this major antigenic site is poorly understood...
November 1, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27768505/the-cost-effectiveness-of-palivizumab-in-infants-with-cystic-fibrosis-in-the-canadian-setting-a-decision-analysis-model
#19
Ashleigh A McGirr, Kevin L Schwartz, Upton Allen, Melinda Solomon, Beate Sander
BACKGROUND: Children with cystic fibrosis (CF) are at higher risk of severe respiratory syncytial virus (RSV) infection, which can lead to a decline in lung function. A monoclonal antibody, palivizumab (PMB), effectively prevents RSV hospitalizations; however, the high cost of PMB, approximately C$10,000 per patient per RSV season, limits its widespread use. We assess the cost-effectiveness of PMB prophylaxis in CF children less than 2 y of age from the Canadian healthcare payer's perspective...
October 21, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27753795/comparing-first-and-second-year-palivizumab-prophylaxis-in-patients-with-hemodynamically-significant-congenital-heart-disease-in-the-caress-database-2005-2015
#20
Abby Li, Daniel Y Wang, Krista L Lanctôt, Ian Mitchell, Bosco A Paes
BACKGROUND: Respiratory syncytial virus hospitalization (RSVH) rates in children less than <2 years of age with hemodynamically significant congenital heart disease (HSCHD) are 2-4 fold higher compared with healthy term infants. Pediatric recommendations differ as to whether palivizumab is beneficial beyond 1 year of age. The objective was to determine whether differences exist in respiratory-related illness hospitalization (RIH) and RSVH in HSCHD infants receiving palivizumab during the first year versus second year of life in the Canadian Registry of Palivizumab (CARESS)...
October 6, 2016: Pediatric Infectious Disease Journal
keyword
keyword
44503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"